Flagship Pioneering’s Collaboration Agreement with Novo Nordisk A/S

Goodwin Procter advised Flagship Pioneering on the deal.

Flagship Pioneering announced its collaboration agreement with Novo Nordisk A/S to create a portfolio of novel research programs to develop transformational medicines.

Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability.

The companies will explore opportunities to apply Flagship’s innovative bioplatforms — an ecosystem that currently comprises 41 companies — to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programs based on these.

This is a novel approach to collaboration, between companies providing extensive access to innovation, leveraging the technology platforms of multiple biotech companies to create a portfolio of medicines across several disease areas.

Novo Nordisk will provide funding for initiated research programs and have an exclusive option to license each program. The ambition is to initiate three to five research programs within the first three years of the collaboration.

The Goodwin team was led by Nancy Urizar, Laurie Burlingame (Picture), and Kingsley Taft.

Involved fees earner: Laurie Burlingame – Goodwin Procter; Kingsley Taft – Goodwin Procter; Nancy Urizar – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Flagship Pioneering;

Martina Bellini

Author: Martina Bellini